Olema Pharmaceuticals (OLMA) Enterprise Value (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Enterprise Value data on file, last reported at -$505.3 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 28.68% year-over-year to -$505.3 million in Q1 2026; TTM through Mar 2026 was -$505.3 million, a 28.68% decrease from a year earlier, with the FY2025 full-year figure at -$505.4 million, down 16.44% from the prior year.
• Enterprise Value for Q1 2026 stood at -$505.3 million, roughly flat from -$505.4 million in the prior quarter.
• Over the last five years, Enterprise Value for OLMA reached as high as -$167.4 million in Q2 2023 and fell as low as -$505.4 million in Q4 2025.
• Historically, Enterprise Value has averaged -$297.6 million across 5 years, with a median of -$261.8 million in 2023.
• Across the five-year window, Enterprise Value soared 30.58% in 2023 and sank 65.8% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$204.4 million in 2022, then retreated by 28.07% to -$261.8 million in 2023, then sank by 65.8% to -$434.1 million in 2024, then retreated by 16.44% to -$505.4 million in 2025, then climbed by 0.02% to -$505.3 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$505.3 million in Q1 2026, -$505.4 million in Q4 2025, and -$329.0 million in Q3 2025.